Currently, there are 111.57M common shares owned by the public and among those 108.98M shares have been available to trade.
The company’s stock has a 5-day price change of 15.46% and -36.81% over the past three months. VKTX shares are trading -38.94% year to date (YTD), with the 12-month market performance down to -65.33% lower. It has a 12-month low price of $18.92 and touched a high of $81.86 over the same period. VKTX has an average intraday trading volume of 4.69 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.78%, -12.28%, and -48.99% respectively.
Institutional ownership of Viking Therapeutics Inc (NASDAQ: VKTX) shares accounts for 73.52% of the company’s 111.57M shares outstanding.
It has a market capitalization of $2.76B and a beta (3y monthly) value of 0.81. The earnings-per-share (ttm) stands at -$1.01. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.37% over the week and 8.52% over the month.
Earnings per share for the fiscal year are expected to decrease by -55.67%, and -34.41% over the next financial year.
Looking at the support for the VKTX, a number of firms have released research notes about the stock. Goldman stated their Neutral rating for the stock in a research note on April 08, 2025, with the firm’s price target at $30. Scotiabank coverage for the Viking Therapeutics Inc (VKTX) stock in a research note released on February 13, 2025 offered a Sector Outperform rating with a price target of $102. B. Riley Securities on their part issued Buy rating on November 22, 2024.
